Clinical Trials Logo

Healthy Participants clinical trials

View clinical trials related to Healthy Participants.

Filter by:

NCT ID: NCT06380205 Not yet recruiting - Clinical trials for Healthy Participants

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Start date: May 7, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the drug interaction between povorcitinib and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.

NCT ID: NCT06372080 Completed - Clinical trials for Healthy Participants

Resistance Training and Hydrolyzed Collagen Supplementation in Healthy Young Adults

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the effects of resistance training with hydrolyzed collagen ingestion on changes in muscle and tendon adaptation in healthy young men and women. The main questions it aims to answer are: - Does resistance training with hydrolyzed collagen ingestion lead to greater changes in tendon properties than resistance training alone? - Does resistance training with hydrolyzed collagen ingestion lead to greater changes in muscle size than resistance training alone? Participants will be randomly assigned to collagen or placebo groups. Participants will perform resistance training three times per week for 10 weeks and hydrolyzed collagen or maltodextrin will be given to collagen or placebo group respectively immediately before each resistance training session. Also, vitamin C will be given to both groups. Researchers will compare collagen and placebo groups to see if hydrolyzed collagen ingestion with resistance exercise would have beneficial effects on changes in muscle and tendon more than resistance training alone. Therefore, using isokinetic dynamometer and ultrasonography, maximal leg strength, morphological, mechanical, and material properties of the patellar tendon and vastus lateralis muscle size and architecture will be assessed.

NCT ID: NCT06368440 Not yet recruiting - Clinical trials for Healthy Participants

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

Start date: May 15, 2024
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral AZD6793 in healthy Japanese and Chinese participants.

NCT ID: NCT06366243 Not yet recruiting - Clinical trials for Healthy Participants

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Start date: May 10, 2024
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the potential of gastric pH-dependent drug-drug interaction effect of esomeprazole, a proton pump inhibitor (PPI), on the pharmacokinetics (PK) of emraclidine in healthy adult participants.

NCT ID: NCT06360445 Completed - Clinical trials for Healthy Participants

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Start date: May 26, 2022
Phase: Phase 1
Study type: Interventional

This Study is a Randomized, Open-Label, 2-formulation, Single-Dose, 2-Period Crossover Bioequivalence Study with a washout period of 7 days. During each session, the subjects were administered a single dose of 100 mg Olaparib Tablets (Test formulation or reference formulation ) under Fasting conditions or 150mg Olaparib Tablets (Test formulation or reference formulation ) under Fasting and Fed conditions. Venous blood samples were collected at pre-dose (0 h), and up to 72 h post dose. This study was to evaluate the bioequivalence and safety of the test formulation and the reference formulation of Olaparib Tablets in healthy subjects.

NCT ID: NCT06357520 Not yet recruiting - Clinical trials for Healthy Participants

A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants

Start date: April 16, 2024
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the effect of itraconazole on the pharmacokinetic (PK) of baxdrostat.

NCT ID: NCT06356948 Recruiting - Clinical trials for Healthy Participants

Rate of Tranexamic Acid Administration on Blood Pressure (RateTXA) Study.

RateTXA
Start date: March 30, 2024
Phase: Phase 4
Study type: Interventional

Tranexamic acid is a well-established treatment for post-partum hemorrhage. This study aims to examine the effect of tranexamic acid administration rates on blood pressure changes over 1 minute compared to 10 minutes in healthy pregnant patients scheduled for cesarean delivery.

NCT ID: NCT06356259 Recruiting - Clinical trials for Healthy Participants

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

Start date: June 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with intravenous(IV) administration of IRX-010 in Healthy Participants.

NCT ID: NCT06350747 Recruiting - Clinical trials for Healthy Participants

The Effect of Laughter Yoga on Nurses' Perceived Stress, Sleep Quality, and Burnout Levels

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The aim of the study was to investigate the effects of laughter yoga on nurses' perceived stress, sleep quality, and burnout levels.

NCT ID: NCT06349473 Recruiting - Clinical trials for Healthy Participants

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with severe Hemophilia A or Hemophilia B, with or without inhibitors (Part B).